Breast cancer is one of the leading causes of cancerrelated death in women in Western countries.
Introduction
Breast cancer is one of the leading causes of cancerrelated death in women in Western countries. 1 Its incidence has increased rapidly in recent years in Taiwan. 2 For most women diagnosed with metastatic breast cancer (MBC), median survival is 18-36 months. 3 Because palliation is an important component of treatment of systemic disease, the goals of therapy are focused on relieving cancer-related symptoms, minimizing treatment-related toxicity, and improving quality of life. Anthracycline and taxane are generally considered to be the most active cytotoxic agents for the management of MBC. 4, 5 However, when patients relapse following anthracycline-and taxane-based chemotherapy, there are few therapeutic options. Efficacious and well-tolerated agents are urgently needed for use in this situation.
ORIGINAL ARTICLE

Sequential Therapy with Capecitabine Followed
by Vinorelbine/Cisplatin in Patients with Anthracycline/Taxane-refractory Metastatic Breast Cancer
Taxane-refractory breast cancer therapy Capecitabine (XELODA; Hoffman-LaRoche, Nutley, NJ, USA), a fluoropyrimidine carbamate, was designed as an orally active drug that would deliver fluorouracil (5-FU) selectively to the tumor. It is an effective palliative agent because of its acceptable toxicity, 6, 7 and has been reported to benefit anthracyclineand taxane-refractory MBC patients. 8, 9 However, a treatment strategy for patients after capecitabine failure has not been identified. Since it is undetermined whether adding to the chemotherapy regimen in capecitabine-failure cases will prolong survival and have palliative effects, further investigation is mandatory. Vinorelbine (VNR) is a newly developed semi-synthetic vinca alkaloid, which chemically differs from the vinblastine-type compounds. 10 Preclinical data have demonstrated a difference in tubulin binding sites of VNR and taxane, suggesting a lack of crossresistance. 11, 12 Vinorelbine has been reported to be an effective agent in taxane-refractory MBC patients. 12, 13 The synergistic antitumor activity of VNR with cisplatin has been demonstrated in animal models, 14 and combination VNR with cisplatin has been reported for anthracycline/taxane-refractory MBC patients. 15, 16 We, therefore, conducted a study to investigate the efficacy and tolerability of sequential therapy with capecitabine followed by a biweekly VNR/cisplatin regimen in anthracycline/taxane-refractory MBC patients.
Methods
Patient eligibility and characteristics
This was an open-label, phase II prospective trial to evaluate the efficacy and safety of sequential therapy of capecitabine followed by biweekly vinorelbine/ cisplatin in anthracycline-and taxane-refractory MBC patients. Patients signed consent forms before entering the study approved by the Taipei Veterans General Hospital Institutional Review Board. Eligibility criteria included histologically proven breast cancer with at least 1 measurable metastatic lesion of 2 × 2 cm. All patients received prior anthracycline and taxane treatment and had documented disease progression during or within 6 months of the last doses of chemotherapy. No more than 2 months elapsed between demonstration of treatment failure and study inclusion. Patients also fulfilled the following pretreatment criteria: life expectancy > -6 months; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; normal bone marrow function (white blood count > -3,000/mm Table 1 . None of the patients received herceptin (trastuzumab) in combination with chemotherapy drugs.
Treatment schema
In the first part of the trial, patients received oral capecitabine (repeated 3-week cycles of 2,500 mg/m 2 twice a day for 2 weeks, followed by 1 week of rest, until disease progression). After failure of capecitabine treatment, the second part of the study divided the patients into 2 groups: biweekly VNR (25 mg/m 2 ) plus cisplatin (40 mg/m 2 ) (arm A), or BSC (arm B) in accordance with patient wishes and clinical judgment. The VNR/cisplatin regimen was administered until the disease progressed or the patient reached a maximal dose (defined as 12 cycles). BSC was defined as measures designed to provide palliation of symptoms and improve quality of life as much as possible without use of any cytotoxic agents after capecitabine failure. The treatment schema of the study is illustrated in Figure 1 .
Dose modifications
Drug dosage was adjusted during the study on the basis of related adverse events as defined by the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), version 1.0. Study treatment was readministered only when the absolute neutrophil count (ANC) reached > -1,500/mm 3 and platelet count was > -7.5 × 10 in cases of creatinine clearance (CCr) 40-60 mL/ minute, and was withheld when CCr <40 mL/minute. If patients developed grade 2 neurologic toxicities, treatment was delayed until recovery to grade 1 or less for a maximum of 2 weeks. If patients suffered from grade 3 neurologic toxicities, treatment was discontinued. The treatment was discontinued permanently if the bilirubin level was higher than 2 times the upper normal limit, or if grade 4 cutaneous toxicity had developed.
Evaluation of treatment response and toxicity
Before initiation of chemotherapy, patients were evaluated by a complete history and physical examination, performance status recording, complete blood cell count, and serum biochemistry. Computed tomography scan was performed for evaluation of the measurable metastatic lesion. Other examinations were performed only in the presence of a clinical indication. Laboratory tests were repeated before the start of each cycle. The tumor response was evaluated every 3 courses of treatment or when disease progression or intolerance to treatment was noted.
The primary endpoints of the study were to investigate the treatment response and toxicity. The tumor response was evaluated by the same radiologist on the basis of the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. 17 In the responsive cases, a confirmatory evaluation was done in 4 weeks. Toxicities were evaluated according to NCI-CTC, version 1.0. The second endpoint was to evaluate the survival differences between patients receiving VNR/cisplatin following capecitabine failure (arm A) and those receiving BSC (arm B).
Statistical analysis
Survival was analyzed using the Kaplan-Meier method, and the significance of difference was examined using a log-rank test. Associations between categorical variables were examined by independent-samples t test, 2 test, or Fisher's exact test (if expected cell number <5). All analyses were performed using the SPSS 12.0 software package for Windows. Statistical significance was defined as p < 0.05.
Results
Treatment response and survival analysis
In the first part of the trial, the overall response rate to capecitabine was 32%, with a complete response rate of 5% (2/37 patients) and a partial response rate of 27% (10/37 patients). Stable disease was achieved in an additional 46% (17/37 patients). The disease control rate with capecitabine was 78%. Median progressionfree survival and overall survival with capecitabine were 5.9 and 9.5 months, respectively (Figure 2 ).
In the second part of the trial, the median number of cycles of biweekly VNR/cisplatin administration was 5 (range, 2-12), and a total of 101 cycles were administered. The response/progression-free survival of capecitabine therapy was balanced in both arms ( Table 1 ). The overall response rate of arm A treated with biweekly VNR/cisplatin was 17% (3/17 patients) and stable disease was 29% (5/17), with a median progression-free survival of 2.9 months (95% CI, 2.6-3.2 months). There was a trend toward better overall survival of arm A patients compared with arm B (BSC) patients, though statistical significance was not reached (10.4 vs. 7.4 months; p = 0.08); however, a significantly better overall survival rate was observed in the subgroup with capecitabinecontrolled disease (10.8 vs. 6.9 months; p = 0.015) (Figure 3 ).
Toxicity
The important adverse effects of capecitabine treatment ( > -NCI-CTC grade 3) included hand-foot syndrome (19%), diarrhea (14%), emesis (16%), and stomatitis (14%). With the VNR/cisplatin regimen, treatmentrelated toxicity was mild and well tolerated. The most common adverse effects were hematologic toxicities: > -grade 3 neutropenia, which occurred in 24% of patients without symptomatic infection, and anemia or thrombocytopenia, which occurred in a few cases. The 6% of patients with grade 4 neutropenia received 25% dose reduction modification. The incidence of non-hematologic toxicities was relatively low (grade 3 neurotoxicity in 1 and grade 3 stomatitis in 1). Treatment was well tolerated by all patients and there was no withdrawal due to treatment-related morbidity/ mortality. The toxicity profile of VNR/cisplatin treatment is given in Table 2 .
Discussion
Adequate management of heavily pretreated MBC is a major issue for treatment of breast cancer. Effective and manageable regimens to achieve maximum palliation, especially in patients who have been pretreated with anthracyclines and taxanes, are still being sought. Previous studies demonstrated the efficacy of capecitabine 8, 9 and VNR/cisplatin in anthracyclineand taxane-refractory MBC; 15, 16 however, the proper order of sequential therapy for heavily pretreated MBC is still undetermined. Our study demonstrates that sequential therapy with capecitabine followed by VNR/cisplatin is a more effective and better tolerated regimen for anthracycline/taxane-refractory MBC than capecitabine alone: the median overall survival was Overall survival Figure 2 . Kaplan-Meier estimated progression-free survival and overall survival curves of 37 MBC patients receiving capecitabine treatment.
10.4 months in the sequential therapy group (arm A) compared with 7.4 months in the capecitabine alone group (arm B). There was a trend toward prolonging overall survival in the sequential therapy group: approximately 3-month survival advantage was observed, though statistical significance was not reached because of the limited case number (p = 0.08). Therefore, subgroup analysis was performed to demonstrate that adding VNR/cisplatin after capecitabine failure does provide a survival benefit in the subgroup with disease controlled by prior capecitabine therapy: the median survival of arm A significantly improved compared with that of arm B (10.8 vs. 6.9 months, p = 0.015). Verma et al 18 reported the 3-month survival benefit of sequential therapy in MBC patients, which was compatible with our result. Our result suggests that sequential capecitabine/VNR-cisplatin prolongs survival in heavily pretreated MBC patients, especially in the subgroup with capecitabine-controlled disease.
One major concern in application of the VNR/ cisplatin regimen is treatment-related myelosuppression. Ray-Coquard et al 16 reported that about 47% of MBC patients receiving weekly VNR plus cisplatin had > -grade 3 neutropenia. Modification of treatment schema to decrease the hematologic toxicity of VNR/ cisplatin is mandatory. Udom et al 19 reported that a biweekly dose of vinorelbine is an effective regimen with markedly decreased toxicity in heavily pretreated patients with advanced breast carcinoma. We, therefore, selected biweekly VNR/cisplatin rather than weekly VNR for our patients, and the toxicity profile of VNR/cisplatin seemed to be manageable: only 24% had > -grade 3 and 6% had grade 4 neutropenia without other complications. This result confirms the safety and tolerability of biweekly VNR plus cisplatin in heavily pretreated MBC patients.
In conclusion, sequential therapy with capecitabine/ VNR-cisplatin is not necessarily effective compared with capecitabine alone, but is probably effective in patients initially controllable with capecitabine. Since the number of patients tested was limited, the effectiveness should be toned down. A larger randomized study is required to confirm our findings.
